医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

OMRON’s First-Quarter Net Sales Climb 3.1%, to Record ¥209.8 Billion, Driven by Growth in Core Industrial Automation Business and Healthcare Business

2018年07月26日 PM04:00
このエントリーをはてなブックマークに追加


 

KYOTO, Japan

OMRON Corporation today announced its consolidated operating results for the first quarter of fiscal 2018, ending June 30, 2018.

Net sales increased 3.1%, to ¥209.8 billion, while gross profit rose 4.3%, to ¥87.7 billion; both new record highs for OMRON. These results boosted the gross profit margin by 0.5 percentage point, to 41.8%, also a record for a fiscal first quarter. Operating income declined 13.6%, to ¥19.6 billion, while net income attributable to shareholders contracted 5.4%, to ¥14.7 billion. Operating and net income fell as a result of an acceleration in forward-looking investments mainly in the Industrial Automation Business. However, OMRON maintains its full year forecast for income gains by fiscal year-end.

Sales in OMRON’s core Industrial Automation Business continued to expand, rising 7.3%, to ¥102.8 billion. This reflected the steady progress of i-Automation, a strategic concept for driving innovations at manufacturing sites targeted at meeting expanding worldwide demand for labor savings and automation. This business generated significant growth by providing optimal solutions to manufacturers in a range of sectors, most notably production investments by Japanese and American automakers and for investment demand in the semiconductor segment. This business was also supported by brisk demand for machinery exports principally in the European food sector, as well as for capital expenditure in Greater China’s growing semiconductor and solar power industries.

Healthcare Business sales advanced 8.5%, to ¥27.9 billion, stemming from favorable sales of blood pressure monitors, nebulizers, and low-frequency therapy equipment. Global online channel sales and more effective efforts to market blood pressure monitors in China made major contributions.

The Company reaffirmed its full-year results forecasts for fiscal 2018. Management forecasts net sales to rise 4.7%, to ¥900.0 billion, gross profit to increase 6.9%, to ¥382.5 billion, operating income to climb 7.8%, to ¥93.0 billion, and net income attributable to shareholders to advance 2.1%, to ¥64.5 billion. The Company plans to acquire treasury stock for a second consecutive year, investing up to ¥20 billion to purchase as many as 5 million shares in the year to July-end 2019. This buy-back plan underscores OMRON’s commitment to improving both shareholder returns and capital efficiency while investing extensively in business growth.

Yoshihito Yamada, OMRON President and CEO, commented that, “In the first quarter, our core Industrial Automation and Healthcare businesses were the main catalysts for growth. We are beginning to see the growth cycle accelerate—net sales growth and wider gross profit margins are enabling us to accrue capital to reinvest in business areas that will drive our growth in the future. OMRON will remain focused on meeting our full year earnings forecasts and achieving mid-to-long term business growth by executing the action plans that we set out at the beginning of the year, while paying close attention to market developments, given growing uncertainties surrounding trade issues.”

 

Financial Highlights

(Billions of yen)

 
   

First quarter of
fiscal 2017

 

First quarter of
fiscal 2018

  Change
Net sales 203.4 209.8 3.1%

Gross profit

84.1 87.7 4.3%

(Gross profit margin)

(41.4%)

(41.8%)

(0.5 percentage points)
Operating income 22.7 19.6 -13.6%
(Operating income margin)

(11.2%)

(9.3%)

(1.8 percentage point)

Net income attributable to
shareholders

15.5 14.7 -5.4%
Yen to U.S. dollar rate 111.5 108.1 -3.4
Yen to euro rate 121.5 129.9 8.4

*Accounting Standards Update (ASU) No. 2017-07 of the FASB, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost is applied to the above results.

 

Fiscal 2018 Forecasts

(Billions of yen)

 
    Fiscal 2017  

Fiscal 2018
forecasts

  Change
Net sales 860.0 900.0 4.7%
Gross profit 357.8 382.5 6.9%
(Gross profit margin) (41.6%) (42.5%) (0.9 percentage point)
Operating income 86.3 93.0 7.8%
(Operating income margin) (10.0%) (10.3%) (0.3 percentage point)

Net income attributable to
shareholders

63.2 64.5 2.1%
Yen to U.S. dollar rate 111.2 107.3 -3.9
Yen to euro rate 129.4 130.7 1.3

*Accounting Standards Update (ASU) No. 2017-07 of the FASB, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost is applied to the above results.

Treasury stock acquisition framework
The Company is acquiring treasury stock to improve capital efficiency, increase shareholder value per share and enhance returns to shareholders.

 

Acquisition details

(1) Category of shares to be acquired:     Common stock of OMRON Corporation
(2) Number of shares to be acquired: Up to 5,000,000 (representing 2.38% of issued shares (excluding treasury stock)
(3) Acquisition amount: Up to ¥20,000,000,000
(4) Acquisition period: July 27, 2018, to July 26, 2019
 

About OMRON Corporation
OMRON Corporation is a global leader in the field of automation based on its core technology of “Sensing & Control + Think.” OMRON’s business fields cover a broad spectrum, ranging from industrial automation and electronic components to automotive electronic components, social infrastructure systems, healthcare, and environmental solutions. Established in 1933, OMRON has about 36,000 employees worldwide, working to provide products and services in 117 countries and regions. For more information, visit OMRON’s website: http://www.omron.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20180726005292/en/

CONTACT

Media contact
OMRON Corporation
Kazunori Yasui,
+81-75-344-7175
Brand Communications Department

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc